Two new medication, the primary able to slowing down the debilitating development of Alzheimer’s illness, have turn out to be embroiled in one of many largest medical controversies in recent times.
For his or her defenders, the medication lecanemab and donanemab signify the primary actual likelihood to combat the illness after many years of analysis — for detractors, they’re one other disappointment after a protracted line of pricey failures.
“We’ve got turned a nook” thanks to those therapies, mentioned British biologist John Hardy, who has been learning Alzheimer’s for the reason that Nineteen Nineties.